
ATYR Stock Forecast & Price Target
ATYR Analyst Ratings
Bulls say
aTyr Pharma Inc. demonstrates a strong positive outlook due to the promising results from its Phase II clinical trial of efzofitimod, which showed clinically meaningful lung function improvements while sparing steroid use in patients with pulmonary sarcoidosis. Additionally, interim data indicates the potential for significant improvement in modified Rodnan skin score (mRSS) in diffuse systemic sclerosis (SSc) patients, suggesting the efficacy of efzofitimod in other fibrotic conditions. The company's focus on expanding its pipeline with the possibility of approval in multiple indications, combined with projected market adoption, positions aTyr Pharma for substantial upside potential.
Bears say
The analysis indicates that aTyr Pharma's revenue opportunity has been significantly diminished due to a clinical setback associated with efzofitimod, with projections now seeing a reduced revenue potential of less than $300 million. Furthermore, there are concerns regarding the drug's developmental progress, as unexpected safety signals, regulatory approval failures, and other setbacks could lead to substantial downward revisions to financial estimates, with a potential downside fair value noted at $0.50 per share. Additionally, the failure in one indication has raised further risks to the drug's viability across other indications, despite some suggested activity observed in earlier trial phases.
This aggregate rating is based on analysts' research of aTyr Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ATYR Analyst Forecast & Price Prediction
Start investing in ATYR
Order type
Buy in
Order amount
Est. shares
0 shares